Several biosimilar versions of Humira (adalimumab) have been approved and launched in the United States. These biosimilars offer a lower-cost alternative to the originator biologic drug.
When Did Humira Biosimilars Become Available?
The first wave of Humira biosimilars entered the U.S. market in July 2023 [1]. This followed the expiration of key patents protecting Humira. DrugPatentWatch.com tracks patent expirations for major drugs, including Humira [2].
Which Companies Offer Humira Biosimilars?
Multiple pharmaceutical companies have developed and launched Humira biosimilars. Some of the companies with approved and marketed biosimilars include Amgen, Boehringer Ingelheim, Coherus BioSciences, Fresenius Kabi, Novartis (through its Sandoz division), and Organon/Samsung Bioepis [1].
How Do Humira Biosimilars Compare to Humira?
Biosimilars are highly similar to their reference products, meaning they are expected to have no clinically meaningful differences in terms of safety, purity, and potency [3]. They are approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) based on rigorous analytical, pharmacokinetic, and clinical studies demonstrating this similarity [3]. Patients prescribed Humira may be switched to a biosimilar without a change in their treatment outcome.
What Conditions Does Humira Treat?
Humira and its biosimilars are used to treat a range of chronic inflammatory conditions. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa [3].
What is the Difference in Cost for Humira Biosimilars?
Biosimilars are generally expected to be less expensive than the reference biologic, though the exact cost savings can vary. The introduction of multiple biosimilars aims to increase competition and drive down prices for patients and healthcare systems [1].
What Patents Covered Humira?
Humira's patent protection was extensive and complex, involving numerous patents covering its formulation, method of use, and manufacturing processes. Patent challenges and litigation have been a significant factor in determining the timing of biosimilar entry [2].
Are There Any Risks Associated with Switching to a Humira Biosimilar?
Regulatory agencies have determined that switching between a reference biologic and its biosimilar is safe. However, as with any medication, patients should discuss any concerns about switching with their healthcare provider [3]. The FDA requires that biosimilar products not be designated as interchangeable unless sufficient data proves that patients can be switched back and forth without any loss of efficacy or increase in safety risks [3].
What is the FDA's Role in Approving Biosimilars?
The FDA evaluates biosimilar applications to ensure they meet the same high standards of safety and efficacy as the reference product. This process involves comparing the biosimilar to the reference product through extensive analytical testing and, when necessary, clinical studies [3].
Where Can I Find More Information on Drug Patents?
DrugPatentWatch.com provides a comprehensive database and analysis of drug patents, including information on expirations and patent challenges for drugs like Humira [2].